ketotifen has been researched along with Diabetes Mellitus, Type 1 in 1 studies
Ketotifen: A cycloheptathiophene blocker of histamine H1 receptors and release of inflammatory mediators. It has been proposed for the treatment of asthma, rhinitis, skin allergies, and anaphylaxis.
ketotifen : An organic heterotricyclic compound that is 4,9-dihydro-10H-benzo[4,5]cyclohepta[1,2-b]thiophen-10-one which is substituted at position 4 by a 1-methylpiperidin-4-ylidene group. A blocker of histamine H1 receptors with a stabilising action on mast cells, it is used (usually as its hydrogen fumarate salt) for the treatment of asthma, where it may take several weeks to exert its full effect.
Diabetes Mellitus, Type 1: A subtype of DIABETES MELLITUS that is characterized by INSULIN deficiency. It is manifested by the sudden onset of severe HYPERGLYCEMIA, rapid progression to DIABETIC KETOACIDOSIS, and DEATH unless treated with insulin. The disease may occur at any age, but is most common in childhood or adolescence.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To investigate the effect of an antiedematous therapy with the histamine antagonist ketotifen on beta-cell function in late prediabetes." | 5.07 | Linear loss of insulin secretory capacity during the last six months preceding IDDM. No effect of antiedematous therapy with ketotifen. ( Bertrams, J; Böhmer, KP; Hübinger, A; Jastram, HU; Kolb, H; Kolb-Bachofen, V; Kuglin, B; Lampeter, EF; Weber, B; Zielasek, J, 1994) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Böhmer, KP | 1 |
| Kolb, H | 1 |
| Kuglin, B | 1 |
| Zielasek, J | 1 |
| Hübinger, A | 1 |
| Lampeter, EF | 1 |
| Weber, B | 1 |
| Kolb-Bachofen, V | 1 |
| Jastram, HU | 1 |
| Bertrams, J | 1 |
1 trial available for ketotifen and Diabetes Mellitus, Type 1
| Article | Year |
|---|---|
Linear loss of insulin secretory capacity during the last six months preceding IDDM. No effect of antiedematous therapy with ketotifen.
Topics: Adolescent; Adult; Autoantibodies; Blood Glucose; Child; Child, Preschool; Diabetes Mellitus, Type 1 | 1994 |